PH12019500530A1 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same - Google Patents
Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using sameInfo
- Publication number
- PH12019500530A1 PH12019500530A1 PH12019500530A PH12019500530A PH12019500530A1 PH 12019500530 A1 PH12019500530 A1 PH 12019500530A1 PH 12019500530 A PH12019500530 A PH 12019500530A PH 12019500530 A PH12019500530 A PH 12019500530A PH 12019500530 A1 PH12019500530 A1 PH 12019500530A1
- Authority
- PH
- Philippines
- Prior art keywords
- formulations
- taste
- making
- dithiole
- thione
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 2
- 239000013078 crystal Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229950008687 oltipraz Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611031046 | 2016-09-12 | ||
| IN201611031045 | 2016-09-12 | ||
| US201662412701P | 2016-10-25 | 2016-10-25 | |
| PCT/IB2017/001231 WO2018047002A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019500530A1 true PH12019500530A1 (en) | 2020-02-24 |
Family
ID=60569946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019500530A PH12019500530A1 (en) | 2016-09-12 | 2019-03-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11185544B2 (enExample) |
| EP (1) | EP3509641A1 (enExample) |
| JP (2) | JP2019533008A (enExample) |
| KR (1) | KR20190089851A (enExample) |
| CN (1) | CN109996563A (enExample) |
| AU (1) | AU2017322544B2 (enExample) |
| BR (1) | BR112019004639A2 (enExample) |
| CA (1) | CA3036630A1 (enExample) |
| PH (1) | PH12019500530A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019531344A (ja) * | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| US11260604B2 (en) * | 2018-03-14 | 2022-03-01 | Andrew Reynolds | Method and system for dispensing molten wax into molds by means of a desktop apparatus |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| CA2408152A1 (en) | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US7012148B2 (en) | 2001-09-25 | 2006-03-14 | Trustees Of Dartmouth College | Compositions and methods for thionation during chemical synthesis reactions |
| US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| US20050182128A1 (en) | 2002-02-13 | 2005-08-18 | Stephen Lam | Use of anethole dithiolethione in lung cancer chemoprevention |
| KR100491318B1 (ko) | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Oltipraz) 제조방법 |
| KR20050014960A (ko) * | 2003-08-01 | 2005-02-21 | 씨제이 주식회사 | B형 간염 치료 및 간 조직 재생용 약제학적 조성물 |
| ZA200604862B (en) | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| PL2486942T3 (pl) | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| FR2879444B1 (fr) | 2004-12-22 | 2007-05-18 | Oreal | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
| US20070036733A1 (en) | 2005-08-12 | 2007-02-15 | Takasago International Corp. (Usa) | Sensation masking composition |
| BRPI0616821B1 (pt) | 2005-08-15 | 2022-06-07 | Givaudan Sa | Método para proporcionar um efeito refrescante em um produto e produto possuindo um efeito refrescante |
| US7803353B2 (en) | 2006-03-29 | 2010-09-28 | The Procter & Gamble Company | Oral care compositions having improved consumer aesthetics and taste |
| GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
| WO2008151460A2 (en) | 2007-06-13 | 2008-12-18 | Givaudan Sa | Cooling compounds |
| US20110003747A1 (en) | 2007-07-20 | 2011-01-06 | Coloumbe Pierre A | Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| EP2244699A2 (en) | 2008-01-31 | 2010-11-03 | Mcneil-PPC, Inc | Edible film-strips for immediate release of active ingredients |
| US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| US8142806B2 (en) | 2008-03-10 | 2012-03-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
| WO2010128026A2 (en) | 2009-05-05 | 2010-11-11 | Givaudan Sa | Organic compounds |
| US10463611B2 (en) * | 2011-06-08 | 2019-11-05 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| ES2632443T3 (es) * | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| WO2014100403A1 (en) | 2012-12-19 | 2014-06-26 | Kashiv Pharma, Llc | Supersaturated stabilized nanoparticles for poorly soluble drugs |
| WO2015023889A1 (en) | 2013-08-16 | 2015-02-19 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
| CA2937766A1 (en) | 2014-02-27 | 2015-09-03 | The Procter & Gamble Company | Oral care compositions with a reduced bitter taste perception |
| WO2016207914A2 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for preparing oltipraz |
| US20160376259A1 (en) * | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
| ITUB20159655A1 (it) | 2015-12-23 | 2017-06-23 | Bormioli Rocco Spa | Capsula di sicurezza di un contenitore. |
| ITUA20162141A1 (it) | 2016-03-31 | 2017-10-01 | Bormioli Pharma Spa | Capsula di chiusura |
| JP2019531344A (ja) * | 2016-09-12 | 2019-10-31 | エスティー アイピー ホールディング エージー | 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
| KR20180123796A (ko) | 2017-05-10 | 2018-11-20 | 서울대학교산학협력단 | Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법 |
-
2017
- 2017-09-12 CA CA3036630A patent/CA3036630A1/en active Pending
- 2017-09-12 BR BR112019004639A patent/BR112019004639A2/pt not_active IP Right Cessation
- 2017-09-12 CN CN201780069887.1A patent/CN109996563A/zh active Pending
- 2017-09-12 JP JP2019535991A patent/JP2019533008A/ja active Pending
- 2017-09-12 AU AU2017322544A patent/AU2017322544B2/en not_active Expired - Fee Related
- 2017-09-12 EP EP17808566.8A patent/EP3509641A1/en active Pending
- 2017-09-12 KR KR1020197010518A patent/KR20190089851A/ko not_active Ceased
-
2019
- 2019-03-12 PH PH12019500530A patent/PH12019500530A1/en unknown
- 2019-03-12 US US16/351,122 patent/US11185544B2/en active Active
-
2021
- 2021-10-25 US US17/509,965 patent/US20220296589A1/en not_active Abandoned
-
2023
- 2023-05-09 JP JP2023077049A patent/JP2023113634A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220296589A1 (en) | 2022-09-22 |
| BR112019004639A2 (pt) | 2019-07-16 |
| JP2019533008A (ja) | 2019-11-14 |
| US11185544B2 (en) | 2021-11-30 |
| CA3036630A1 (en) | 2018-03-15 |
| US20190209557A1 (en) | 2019-07-11 |
| AU2017322544B2 (en) | 2022-06-02 |
| AU2017322544A1 (en) | 2019-05-02 |
| EP3509641A1 (en) | 2019-07-17 |
| JP2023113634A (ja) | 2023-08-16 |
| CN109996563A (zh) | 2019-07-09 |
| KR20190089851A (ko) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ742208A (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| MX2018006207A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| EP4385521A3 (en) | Storage stable compositions and methods for the treatment of refractive errors of the eye | |
| MX2017008520A (es) | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| CA2989145C (en) | IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES | |
| EA201791560A1 (ru) | Порошковый состав для интраназального введения для лечения гипогликемии | |
| WO2018047013A8 (en) | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same | |
| MX2021000189A (es) | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias. | |
| EA201592238A1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
| PH12017502123A1 (en) | Substituted benzamides and methods of use thereof | |
| EP3622060A4 (en) | SULFAMIDASE (SGSH) VARIANTS, VECTORS, COMPOSITIONS AND METHODS AND USES FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE IIIA (MPS IIIA) | |
| ZA201807446B (en) | Improved drug formulations | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| WO2019171174A3 (en) | Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof |